中药联合西药治疗COVID-19疗效与安全性的系统评价与Meta分析
该系统评价与Meta分析检索2020年1月至2021年6月多个数据库,纳入22项高质量随机对照试验共1789例受试者,评估中药联合西药治疗不同严重程度COVID-19的疗效与安全性。结果显示,与单纯西药相比,中药联合西药组总有效率更高、症状评分更低、病毒转阴时间更短、CT影像与血液结果改善更优、总不良事件更少(P<0.05),亚组分析显示轻中度患者总有效率显著更高,但死亡率与不良事件无显著差异。
要点
- 中药联合西药治疗COVID-19可提高总有效率,尤其对轻度和中度患者。
- 联合治疗可改善发热、咳嗽、乏力、咽干、咽痛症状及CT影像和血液结果。
- 联合治疗未增加不良事件,但未报告严重不良事件和长期结局。
核心结论
- 当前证据支持中药联合西药治疗COVID-19的疗效和安全性,尤其对轻中度症状患者。
- 联合治疗在死亡率与不良事件方面与单纯西药无显著差异。
- 长期疗效有待进一步研究。
研究设计与样本
- 系统评价与Meta分析,检索CNKI、PubMed、万方、ClinicalTrials.gov、Embase、ChiCTR和ICTRP,时间2020年1月1日至2021年6月30日。
- 纳入22项高质量随机对照试验,共1789例受试者。
- 采用RevMan 5.4.1进行Meta分析,使用GRADE评估证据质量,研究注册号INPLASY202210072。
主要发现
- 与单纯西药相比,中药联合西药组总有效率更高(P<0.05)。
- 联合治疗组发热、咳嗽、乏力、咽干、咽痛症状评分更低(P<0.05)。
- 联合治疗组平均病毒转阴时间更短,CT影像和血液结果改善更优(P<0.05)。
- 联合治疗组总不良事件和病情恶化更少(P<0.05)。
- 亚组分析显示轻度和中度患者联合治疗组总有效率显著高于西药组。
关键数值与推荐
- 主要结局为总有效率,次要结局包括症状改善和总不良事件率。
- 亚组分析按COVID-19不同严重程度评估。
- 未发现联合治疗与单纯西药在死亡率和不良事件方面有显著差异。
临床怎么用
- 对于轻度和中度COVID-19患者,可考虑中药联合西药治疗以提高总有效率并改善症状。
- 联合治疗可能缩短病毒转阴时间并改善CT影像和血液结果。
- 需关注不良事件,尽管未报告严重不良事件。
局限性
- 未检索到单用中药或安慰剂/无治疗对照的试验。
- 未报告严重不良事件和长期结局。
- 纳入研究间异质性未详细说明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To systematically review the clinical efficacy and safety of Chinese herbal medicine (CHM) with and without Western medicine (WM) for different severity of COVID-19. METHODS: CNKI, PubMed, Wanfang Database, ClinicalTrails.gov, Embase, ChiCTR and ICTRP were searched from 01 Jan, 2020 to 30 Jun, 2021. Two authors independently assessed all the randomized clinical trials (RCTs) for trial inclusion, data extraction and quality assessment. Meta-analysis was conducted using Review Manager software (RevMan 5.4.1). Evidence was assessed using Grading of Recommendations Assessment, Development, and Evaluation (GRADE). Primary outcomes included total effectiveness rate. Secondary outcomes included improvements in symptom improvement and total adverse event rate. Different severity of COVID-19 patients was assessed in subgroup analysis. This study was registered with INPLASY, INPLASY202210072. RESULTS: 22 high quality RCTs involving 1789 participants were included. There were no trial used CHM alone nor compare placebo or no treatment. Compared with WM, combined CHM and WM (CHM-WM) treatment showed higher total effectiveness rate, lower symptom scores of fever, cough, fatigue, dry throat and pharyngalgia, shorter mean time to viral conversion, better Computerized Tomography (CT) image and blood results, fewer total adverse events and worse conditions (P < 0.05). Subgroup analysis showed that the total effectiveness rate of combined CHM-WM group was significantly higher than WM group, especially for mild and moderate patients. No significant differences in mortality and adverse events were found between combined CHM-WM and WM treatment. No serious adverse events and long-term outcomes were reported. CONCLUSION: Current evidence supported the therapeutic effects and safety of combined CHM-WM treatment on COVID-19, especially for patients with mild and moderate symptoms. Long-term effects of therapy are worthy in further study.
引用
- Li L, Xie H, Wang L, et al. The efficacy and safety of combined chinese herbal medicine and western medicine therapy for COVID-19: a systematic review and meta-analysis. Chin Med. 2022. PMID: 35729581. doi:10.1186/s13020-022-00600-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。